What it's for (Indications)
- Eprosartan is primarily indicated for the treatment of essential hypertension.
- It can be used alone or in combination with other antihypertensive agents to lower blood pressure in adult patients.
- Effective blood pressure control with eprosartan reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions, and can help prevent the progression of end-organ damage associated with chronic hypertension, such as renal impairment and heart failure.
- Its efficacy in various patient populations, including the elderly and those with renal impairment, has been established, making it a valuable option in hypertension management.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The usual recommended starting dose of eprosartan for the treatment of hypertension in adults is 400 mg once daily, administered orally, with or without food. The dose may be increased to a maximum of 600 mg once daily, or 300 mg twice daily, to achieve optimal blood pressure control, depending on the patient's response and tolerability. For patients with mild to moderate hepatic impairment, a starting dose of 400 mg once daily is generally appropriate, but caution and close monitoring are advised. In patients with renal impairment, no initial dose adjustment is typically required unless severe, but vigilant monitoring of renal function and potassium levels is essential. Dose adjustments should be made based on blood pressure response after approximately 2 to 4 weeks of therapy. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions associated with eprosartan therapy are generally mild and transient, including dizziness, fatigue, headache, and upper respiratory tract infection.
- Other less frequent but notable side effects may include orthostatic hypotension, particularly at the initiation of therapy or with dose escalation.
- Hyperkalemia, while less common, can occur, especially in patients with renal impairment, diabetes mellitus, or those concurrently taking potassium-sparing diuretics or potassium supplements.
- Renal function deterioration, manifested as increases in serum creatinine and blood urea nitrogen (BUN), may also be observed, particularly in patients with pre-existing renal artery stenosis.
- Angioedema, a rare but serious adverse event, requires immediate medical attention.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** Eprosartan can cause fetal harm when administered to a pregnant woman. The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios, which may result from decreased fetal renal function, has also been reported and is associated with fetal limb contractures, craniofacial deformation, and lung hypoplasia. If pregnancy is detected, eprosartan should be discontinued as soon as possible. These adverse outcomes are typically not observed when exposure occurs prior to the second trimester. All women of childbearing potential should be made aware of the potential risks to the fetus if they become pregnant during eprosartan therapy.
- Eprosartan, like other angiotensin II receptor blockers, carries several important warnings.
- Symptomatic hypotension may occur, especially in patients who are volume-depleted or salt-depleted, such as those receiving high-dose diuretics.
- Careful monitoring is advised at the initiation of therapy.
- Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by combining eprosartan with an ACE inhibitor or aliskiren is generally not recommended, especially in patients with diabetes or renal impairment, due to an increased risk of hypotension, hyperkalemia, and renal function deterioration compared to monotherapy.
- Patients with severe congestive heart failure whose renal function depends on the activity of the RAAS may be at risk of oliguria, progressive azotemia, and acute renal failure upon treatment with eprosartan.
- Regular monitoring of renal function and serum potassium levels is crucial throughout treatment.
How it Works (Mechanism of Action)
Eprosartan is a highly selective angiotensin II receptor blocker (ARB), specifically targeting the AT1 receptor subtype. By competitively blocking the binding of angiotensin II to the AT1 receptor, eprosartan effectively inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This blockade leads to peripheral vasodilation, reducing systemic vascular resistance, and consequently lowering blood pressure. Furthermore, it attenuates the deleterious effects of angiotensin II on cardiac and vascular remodeling, including hypertrophy and fibrosis. Unlike ACE inhibitors, ARBs do not inhibit the breakdown of bradykinin, which may contribute to a lower incidence of cough. The inhibition of aldosterone secretion also promotes sodium and water excretion, further contributing to its antihypertensive effect.
Commercial Brands (Alternatives)
No other brands found for this formula.